Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14703378 | 1.00 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2HTTGAA | |
| Hydrochloric Acid SCHEMBL17668293 | 0.99 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2HTTGAA | |
| Hydrochloric Acid SCHEMBL17668288 | 0.99 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2HTTGAA | |
| SCHEMBL14703477 | 0.99 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2HTTGAA | |
| Hydrochloric Acid SCHEMBL17668295 | 0.97 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2HTTGAA | |
| SCHEMBL14703383 | 0.86 | MCHR1 (0.50) | NPC1RAB9ASMN1; SMN2HTTGAA | |
| SCHEMBL19393790 | 0.86 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2HTTGAA | |
| SCHEMBL14703253 | 0.86 | TSHR (0.50) | NPC1RAB9ASMN1; SMN2HTTGAA | |
| SCHEMBL17777313 | 0.86 | MCHR1 (0.50) | NPC1RAB9ASMN1; SMN2HTTGAA | |
| SCHEMBL14703671 | 0.85 | KMT2A (0.48) | NPC1RAB9ASMN1; SMN2HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742020-B1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | IMMUNOMET THERAPEUTICS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9321742-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321742-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| WO-2013022279-A2 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KR) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | PRKAG1, GCKR, GPR119 | NPC1 308/4885RAB9A 1508/4885SMN1; SMN2 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.